I agree with your entire post. With that said the revenue I believe is at the crux of what we are seeing. Is it possible that we get revenue before we complete CD16? Yes.
Is it likely? We don't know.
Is the door open for an EUA in US? Possible, but we don't know. Obviously that would change things dramatically.
Short of that we are looking at revenue from other countries or the completion of this trial. I hope that we can find revenue in other countries, as I worry that this trial is going to take a while to enroll.
It's hard to quantify how the negative force of declining.cases compares to the positive force of having some data to share with doctors and patients to help with enrollment. We simply don't know.
All of this to say, uncertainty causes stocks to drop. I suspect if we show progress in these areas we will see the price rebound. But, we will have to wait and see.
Is it likely? We don't know.
Is the door open for an EUA in US? Possible, but we don't know. Obviously that would change things dramatically.
Short of that we are looking at revenue from other countries or the completion of this trial. I hope that we can find revenue in other countries, as I worry that this trial is going to take a while to enroll.
It's hard to quantify how the negative force of declining.cases compares to the positive force of having some data to share with doctors and patients to help with enrollment. We simply don't know.
All of this to say, uncertainty causes stocks to drop. I suspect if we show progress in these areas we will see the price rebound. But, we will have to wait and see.
1
